UMB Bank n.a. Has $71,000 Position in Repligen Corporation $RGEN

UMB Bank n.a. lowered its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 14.6% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 569 shares of the biotechnology company’s stock after selling 97 shares during the period. UMB Bank n.a.’s holdings in Repligen were worth $71,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Alliance Wealth Advisors LLC UT raised its position in shares of Repligen by 2.5% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 89 shares during the last quarter. State of Michigan Retirement System raised its position in Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $1,585,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock worth $1,858,000 after purchasing an additional 100 shares in the last quarter. State of Wyoming raised its position in Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 115 shares in the last quarter. Finally, Signaturefd LLC raised its position in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock opened at $121.68 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a market cap of $6.85 billion, a P/E ratio of -486.70, a P/E/G ratio of 2.30 and a beta of 1.07. The firm has a 50 day simple moving average of $120.04 and a 200 day simple moving average of $125.93. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the business earned $0.40 EPS. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Barclays assumed coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. Evercore ISI raised shares of Repligen from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $130.00 to $155.00 in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Wednesday, September 3rd. Finally, Jefferies Financial Group dropped their price objective on shares of Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, September 12th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average price target of $168.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.